Cardiac Ablation Market size is anticipated to surpass USD 5 billion by the end of 2035, growing at a CAGR of 13% during the forecast period, i.e., 2023-2035. In the year 2022, the industry size of cardiac ablation was over USD 3 billion. The growth of the market can be attributed to growing consumption of alcohol, tobacco and substance abuse which is further boosting the prevalence for cardiac ailments. According to a new brief released by the World Health Organization, the World Heart Federation, and the University of Newcastle Australia ahead of World Heart Day, which is observed on September 29, 1.9 million people per year pass away from tobacco-induced heart disease.
Smoking and the consumption of any other substances greatly affect the functioning of the heart, along with all other body parts. According to the FDA, the poisonous mixture of more than 7,000 chemicals in cigarette smoke could interfere with vital bodily functions when it is inhaled, causing serious health problems. Getting oxygen-rich blood to the heart and the rest of the body is one of processes of inhaling. When a person breathes, the lungs receive oxygen and send it to the heart, which then circulates this blood throughout the rest of the body via the blood arteries. In addition, when people inhale cigarette smoke, the blood that is circulated to the rest of the body picks up the compounds in the smoke. These substances could harm the blood vessels and heart, which could result in cardiovascular disease (CVD) or other heart disease.
Growth Drivers
Challenges
|
Base Year |
2022 |
|
Forecast Year |
2023-2035 |
|
CAGR |
13% |
|
Base Year Market Size (2022) |
USD 3 Billion |
|
Forecast Year Market Size (2035) |
USD 5 Billion |
|
Regional Scope |
|
Technology (Radiofrequency, Electrical, Cryoablation, Ultrasound, Microwave)
The global cardiac ablation market is segmented and analyzed for demand and supply by technology into radiofrequency, electrical, cryoablation, ultrasound, and microwave. Out of which, the radiofrequency segment is anticipated to garner the highest revenue by the end of 2035. The growth of the cardiac ablation market can be attributed to the growing number of cardiovascular diseases all around the globe. According to the World Health Organization, the main cause of death worldwide is cardiovascular disease (CVD). In 2019, 32% of all fatalities worldwide were attributable to CVDs, killing an estimated 17.9 million individuals. Heart attacks and strokes were to blame for 85% of these deaths. Radiofrequency has been used to create percutaneous left heart access and has been proven effective at reanalyzing the central and peripheral arteries. Moreover, it is known to be safe and effective in treating heart disease. Moreover, the ultrasound segment is anticipated to grow significantly over the forecast period, backed by growing demand for ultrasound devices.
Application (Cardiac Arrhythmia, Atrial Fibrillation, Tachycardia, Open Surgery)
The global cardiac ablation market is also segmented and analyzed for demand and supply by application into cardiac arrhythmia, atrial fibrillation, tachycardia, and open surgery. Amongst these segments, the atrial fibrillation segment is anticipated to grow significantly over the forecast period, backed by its growing frequency. Moreover, the growing consumption of alcohol and smoking is also estimated to boost the frequency of atrial fibrillation. Additionally, growing intake of caffeine is also anticipated to drive the growth of the segment in the cardiac ablation market. Also, atrial fibrillation risk is higher in people with specific chronic illnesses such as diabetes, metabolic syndrome, chronic renal disease, lung disease, or sleep apnea. Blood could build up and form clots in the upper chambers of the heart (atria) as a result of the disorderly cardiac rhythm in atrial fibrillation. A stroke may result from a blood clot in the left atrium of the heart that escapes and travels to the brain. As a person ages, the risk of stroke from atrial fibrillation increases. Hence, the treatment for atrial fibrillation is necessary. Further, this is estimated to boost the demand for effective cardiac rhythm management. Therefore, owing to the growth in this segment, the market is expected to grow further.
Our in-depth analysis of the global cardiac ablation market includes the following segments:
|
By Technology |
|
|
By Product |
|
|
By Application |
|
North American Market Forecast
The North American cardiac ablation market, amongst the market in all the other regions, is projected to hold the largest market share by the end of 2035, backed by the presence of key pharmaceutical equipment companies, along with rise in number of clinical trials. Moreover, the prevalence of heart disease is also high in this region which is also estimated to boost the growth of the cardiac ablation market in this region. Most prevalent form of heart disease, coronary heart disease (CHD), claims the lives of over 382,820 people each year in United States. Almost 805,000 people experience a heart attack each year. 605,000 of these result in a first-time heart attack, while 200,000 are caused by previous heart attacks. Further, there has been growing investment made in the development of cardiac ablators and rise in technological advancement, which would further enhance productivity which would also boost the cardiac ablation market growth in this region.
APAC Market Statistics
The Asia Pacific cardiac ablation market, amongst the market in all the other regions, is projected to grow with the highest CAGR during the forecast period. The growth of the market in this region can be attributed to the growing geriatric population who are prone to cardiovascular disease. However, adults as well as young people in this region are estimated to diagnose with cardiovascular disease. Although, it has less than 20% of the global population, according to estimates from the Indian Heart Association, India is responsible for over 60% of the burden of heart disease worldwide. This may be attributed to a genetic susceptibility to metabolic dysregulation and cardiomyopathy, as well as a recent change in modifiable risk factors towards increased consumption of red meat, saturated fats, and trans fats, junk foods, and higher levels of stress. Hence, the adoption of cardiovascular disease treatment is estimated to increase in this region, further boosting the market growth. Moreover, there has been a rise in manufacturers of ablation in this region, which is estimated to influence the growth of the cardiac ablation market.
Medtronic, announced the signing of a formal agreement to purchase Affera, Inc., a privately held medical technology business situated in the Boston region. For the treatment of patients with cardiac arrhythmias (irregular heartbeats) such atrial fibrillation, Affera develops and produces catheter-based cardiac ablation technologies, such as a unique localized pulsed field ablation solution (AF).
Biosense Webster, Inc., a subsidiary of Johnson & Johnson MedTech, announced the availability of the OCTARAY Mapping Catheter with TRUEref Technology, which is driven by the CARTO 3 Version 7 System. Atrial fibrillation and other cardiac arrhythmias were produced using the OCTARAY Mapping Catheter (AFib).
Author Credits: Radhika Gupta, Shivam Bhutani
FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.
Have questions before ordering this report?